18.2 Particulate, Liquid & Oncologic Embolization

Key Takeaways

  • Gelatin, particles, glue and precipitating liquids have distinct mechanisms. Choose using the actual product, route and anatomy.

  • The TRUFILL D5W flush and Onyx DMSO-compatible delivery are different, label-specific requirements.

  • Conventional TACE, drug-eluting bead TACE and Y-90 therapy differ in what they deliver and how they act.

  • A lung shunt percentage is separate from lung activity and dose. Apply the U.S. instructions for the prescribed radioembolization product.

Last updated: November 2026

18.2 Particulate, Liquid & Oncologic Embolization

Clinical Core: Match the embolic mechanism to the planned vessel or tissue target. Check device and catheter compatibility, identify pathways to healthy tissue and watch for reflux or shunting. Use the applicable U.S. labeling for any named product.

Particulate embolics

AgentHow it works and what to verify
Absorbable gelatinGelatin can obstruct flow and provide a matrix for thrombosis, with temporary intent. Resorption and recanalization vary. The U.S. Gelfoam sterile compressed sponge label contraindicates intravascular placement and discusses reported complications of unapproved embolization use. Verify the specific product instead of generalizing from the material.
Irregular polyvinyl alcohol particlesParticles can lodge downstream and promote local occlusion. Irregular shapes may aggregate, causing a more proximal effect or delivery difficulty.
Calibrated microspheresA defined size range helps control penetration. Compressibility, suspension, flow and anatomic communications still affect where particles lodge.

A selected uterine fibroid embolization targets fibroid perfusion while monitoring the rest of the uterine and ovarian circulation. The U.S. Embosphere instructions specify against using spheres smaller than 500 µm for uterine fibroid embolization. Apply this to the named product and indication. In prostatic artery embolization for selected lower urinary tract symptoms associated with benign prostatic hyperplasia, identify rectal, bladder and penile pathways that could carry particles outside the target. The product chart, measured anatomy and the operator's angiographic endpoint guide selection.

Liquid embolics

N-butyl cyanoacrylate (n-BCA) solidifies through anionic polymerization on contact with body fluids or tissue. The ethiodized oil in the TRUFILL system provides radiopacity and retards polymerization. Its updated U.S. labeling includes selected presurgical devascularization of cerebral AVMs and certain middle meningeal artery embolizations as an adjunct to surgery for symptomatic subacute or chronic subdural hematoma. It specifies a 5% dextrose-in-water flush and compatible accessories. An ionic flush can promote premature polymerization. Reflux and catheter entrapment are serious risks, so placement and withdrawal follow the system instructions and operator assessment.

Ethylene vinyl alcohol (EVOH) in the Onyx formulation is dissolved in dimethyl sulfoxide (DMSO) with radiopaque tantalum. As the solvent diffuses away, the polymer precipitates into a cast. The specified DMSO-compatible microcatheter and its preparation requirements are essential. A precipitating agent can still trap a catheter mechanically. Refer to the specific formulation and U.S. indication rather than transferring instructions across products or regions.

Ethanol is a sclerosant that injures the endothelium. In selected malformation treatment, systemic passage can raise pulmonary arterial pressure and cause cardiovascular collapse. Dose and monitoring depend on the selected protocol, lesion and measured response. The ability to measure the volume alone does not establish a safe limit.

Hepatic arterial treatments

Normal liver parenchyma has arterial and portal inflow. Many hepatocellular carcinomas depend heavily on arterial perfusion, which can support selective treatment. Liver function, arterial variants, portal patency and non-target branches influence safety. A variant hepatic branch may arise separately from the celiac path (§14.1), and planned therapy may need multiple mapping runs.

TreatmentDelivery
Conventional transarterial chemoembolization (cTACE)Delivers an arterial chemotherapy and iodized-oil emulsion for the selected target, commonly followed by an embolic to slow supply.
Drug-eluting bead TACEUses selected drug-loaded beads for embolization and local drug release. Systemic exposure and treatment complications can still occur.
Transarterial radioembolization (TARE)Delivers yttrium-90 glass or resin microspheres to provide local beta radiation. Product indication and dosimetry requirements differ.

Before TARE, map arterial supply and possible pathways to stomach, duodenum or other extrahepatic organs. Select a safe infusion location and manage at-risk branches as indicated. A gastroduodenal branch identified on a map does not by itself require coiling. Technetium-99m macroaggregated albumin (MAA) distribution from the planned delivery site estimates treatment distribution. Nuclear imaging evaluates lung exposure and other non-target activity. The U.S. TheraSphere label contraindicates gastrointestinal MAA deposition that angiographic techniques cannot correct. Check the selected product for its own non-target criteria.

Lung shunt fraction is the estimated fraction of activity going to the lungs. A count-based example uses matched, processed lung and liver counts: LSF=100×Clung/(Clung+Cliver)\text{LSF}=100\times C_{\text{lung}}/(C_{\text{lung}}+C_{\text{liver}}). Shunt fraction, lung activity and absorbed dose are distinct. The 2025 U.S. SIR-Spheres IFU lists contraindications of greater than 20% lung shunting or doses greater than 30 Gy in one treatment or 50 Gy cumulatively on retreatment. The U.S. TheraSphere label instead specifies a shunt contraindication based on estimated lung activity exceeding 0.61 GBq and gives dose guidance of 30 Gy per treatment and 50 Gy combined, with its stated dosimetry assumptions. Use the product and full plan before judging eligibility.

Worked example. Processed counts are 22,000 lung and 78,000 liver. The estimated lung fraction is 22,000/100,000=0.2222{,}000/100{,}000=0.22, or 22%. The result alone exceeds the stated SIR-Spheres fraction criterion. An activity or dose criterion requires the relevant planning model and inputs. Report the measured data, the product and the unresolved safety question to the team.

Loading diagram...
Embolic Selection and Radioembolization Mapping
Test Your Knowledge

A technologist preparing the named TRUFILL n-BCA system finds the planned microcatheter was last flushed with saline. Which setup concern should be raised before delivery?

A

The saline concentration changes the measured lung shunt.

B

The TRUFILL instructions specify D5W preparation because ionic contact can trigger premature polymerization.

C

The device requires the same DMSO solvent setup as Onyx.

D

The catheter should be used without checking accessory compatibility.

Test Your Knowledge

The team plans uterine fibroid embolization with U.S. Embosphere microspheres. A package lists 300–500 µm. Which action fits the named instructions?

A

Proceed because the upper size on the package equals 500 µm.

B

Choose this range because it applies to every uterine embolic indication.

C

Flag the size range because it includes spheres smaller than the labeled minimum for this use.

D

Treat sizing as irrelevant if the catheter can pass the particles.

Test Your Knowledge

Processed MAA counts are 22,000 in the lungs and 78,000 in the liver. The team is evaluating the 2025 U.S. SIR-Spheres label. What do these numbers establish?

A

The 22% shunt exceeds this product’s listed fraction criterion. Report it for plan review.

B

A safe lung absorbed dose of 22 Gy has already been established.

C

The shunt is 28.2% because liver counts are the only denominator.

D

The shunt is below 20% after the lung and liver counts are added.

Sections you finish are checked off in the contents.